AVTX vs BBLG

Avalo Therapeutics, Inc. vs Bone Biologics Corp — Valuation Comparison 2026

AVTX

Biotechnology
Avalo Therapeutics, Inc.
Quality
4.7
out of 10
Value Trap
49
WARN
Price
$16.13
Last close
Models
9/13
Active
VS

BBLG

Biotechnology
Bone Biologics Corp
Quality
3.7
out of 10
Value Trap
12
SAFE
Price
$1.30
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType AVTX Fair ValueAVTX Upside BBLG Fair ValueBBLG Upside
Bayesian DCF Intrinsic $4.59 -71.6% $1.73 +32.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.69 -95.7% $0.30 -76.9%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for AVTX vs BBLG — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AVTX vs BBLG — Which Stock Is More Undervalued?

AVTX scores higher with a 4.7/10 quality rating vs BBLG's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Avalo Therapeutics, Inc. (AVTX) and Bone Biologics Corp (BBLG) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AVTX currently trades at $16.13 with a QOC of 4.7/10, while BBLG trades at $1.30 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).